Pfizer vaccine recipients have lower neutralizing antibodies targeting delta variant up to three months after first dose. Outcome data needed to determine if this translates into less efficacy. Study concludes second dose interval needs to be shortened.

Dr. Barry Dworkin

Medical Mythbusting Commentary for June 4, 2021

Pfizer vaccine recipients have lower neutralizing antibodies targeting delta variant up to three months after first dose. Outcome data needed to determine if this translates into less efficacy. Study concludes second dose interval needs to be shortened. Play Now | Play in Popup | Download

Source:
Pfizer vaccine recipients have lower antibodies targeting Indian variant – study
Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant

Reference:
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Related posts:

  1. New ‘pandemic potential’ flu strain found in pigs. Also, Face Mask Follies: A Revisit to Dunning-Krugerville
  2. Silent spreaders of SARS-CoV-2 seem to contribute to a substantial number of U.S. cases. Ever the more reason to implement consistent face mask and physical distancing policies.
  3. There is still too much we do not know to say that people with asymptomatic Covid-19 are “the key to ending the pandemic”
  4. Little being done to mitigate the unsurprising exponential increase of Covid-19 cases in Ontario. Why not employ successful measures that other countries are using to protect their citizens and remain economically functional?
Bitnami